{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:39:38Z","timestamp":1772156378874,"version":"3.50.1"},"posted":{"date-parts":[[2023,11,23]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":26,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    The only licensed malaria vaccine, RTS,S\/AS01\n                    <jats:sub>E<\/jats:sub>\n                    , confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how vaccine dosing regimen affects vaccine efficacy (VE).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    1,500 children aged 5\u201317 months were randomized to receive four different RTS,S\/AS01\n                    <jats:sub>E<\/jats:sub>\n                    regimens or a rabies control vaccine in a phase 2b clinical trial in Ghana and Kenya. We evaluated the time to the first new genotypically detected infection and the total number of new infections during two follow-up periods in over 36K participant specimens. We performed a post hoc analysis of VE based on malaria infection status at first vaccination and force of infection.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    We observed significant and comparable VE (25\u201343%, 95% CI union 9\u201353%) against first new infection for all four RTS,S\/AS01\n                    <jats:sub>E<\/jats:sub>\n                    regimens across both follow-up periods (12 and 20 months). Each RTS,S\/AS01\n                    <jats:sub>E<\/jats:sub>\n                    regimen significantly reduced the number of new infections in the 20-month follow-up period (control mean 4.1 vs. RTS,S\/AS01\n                    <jats:sub>E<\/jats:sub>\n                    mean 2.6\u20133.0). VE against first new infection was significantly higher in participants who were malaria-infected (68%; 95% CI, 50 to 80%) versus uninfected (37%; 95% CI, 23 to 48%) at the first vaccination (P=0.0053) and in participants experiencing greater force of infection between dose 1 and 3 (P=0.059).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    All tested dosing regimens blocked some infections to a similar degree. Improved VE in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation. (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    number,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03276962\">NCT03276962<\/jats:ext-link>\n                    )\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.11.22.23298907","type":"posted-content","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T21:45:11Z","timestamp":1700775911000},"source":"Crossref","is-referenced-by-count":0,"title":["Baseline malaria infection status and RTS,S\/AS01E malaria vaccine efficacy"],"prefix":"10.64898","author":[{"given":"Michal","family":"Juraska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Early","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen F.","family":"Schaffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Khorgade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima S.","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laina D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsiri","family":"Agbenyega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ansong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis K.","family":"Bii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.Y.","family":"Buabeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"English","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonna","family":"Grimsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon K.","family":"Kariuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kephas","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelli","family":"Westercamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian F.","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Opokua","family":"Ofori-Anyinam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwyn L.","family":"MacInnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dyann F.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Neafsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023112623401502000_2023.11.22.23298907v1.1","unstructured":"World malaria report 2022 [Internet]. [cited 2023 May 17];Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240064898"},{"key":"2023112623401502000_2023.11.22.23298907v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2015.11.015"},{"key":"2023112623401502000_2023.11.22.23298907v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00273-0"},{"key":"2023112623401502000_2023.11.22.23298907v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505819"},{"issue":"9","key":"2023112623401502000_2023.11.22.23298907v1.5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"2023112623401502000_2023.11.22.23298907v1.6","doi-asserted-by":"crossref","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","article-title":"PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection","volume":"17","year":"2021","journal-title":"PLoS Pathog"},{"key":"2023112623401502000_2023.11.22.23298907v1.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2002.00773.x"},{"key":"2023112623401502000_2023.11.22.23298907v1.8","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"issue":"1","key":"2023112623401502000_2023.11.22.23298907v1.9","first-page":"31","article-title":"The relative performance of targeted maximum likelihood estimators","volume":"7","year":"2011","journal-title":"Int J Biostat"},{"issue":"4","key":"2023112623401502000_2023.11.22.23298907v1.10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s10985-015-9353-9","article-title":"Mark-specific hazard ratio model with missing multivariate marks","volume":"22","year":"2016","journal-title":"Lifetime Data Anal"},{"key":"2023112623401502000_2023.11.22.23298907v1.11","unstructured":"Heng F , Sun Y , Gilbert PB . Estimation and Hypothesis Testing of Strain-Specific Vaccine Efficacy with Missing Strain Types, with Applications to a COVID-19 Vaccine Trial [Internet]. 2022 [cited 2023 Mar 4];Available from: http:\/\/arxiv.org\/abs\/2201.08946"},{"issue":"2","key":"2023112623401502000_2023.11.22.23298907v1.12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/biom.12016","article-title":"Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy","volume":"69","year":"2013","journal-title":"Biometrics"},{"issue":"2","key":"2023112623401502000_2023.11.22.23298907v1.13","first-page":"65","article-title":"A Simple Sequentially Rejective Multiple Test Procedure","volume":"6","year":"1979","journal-title":"Scand J Stat"},{"key":"2023112623401502000_2023.11.22.23298907v1.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x)"},{"issue":"7743","key":"2023112623401502000_2023.11.22.23298907v1.15","first-page":"169","article-title":"Immunosuppression in children with malaria","volume":"1","year":"1972","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"2023112623401502000_2023.11.22.23298907v1.16","first-page":"253","article-title":"Immunosuppression in murine malaria","volume":"33","year":"1977","journal-title":"II. The primary response to bovine serum albumin. Immunology"},{"key":"2023112623401502000_2023.11.22.23298907v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/312449a0"},{"key":"2023112623401502000_2023.11.22.23298907v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.4.763"},{"key":"2023112623401502000_2023.11.22.23298907v1.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4193"},{"key":"2023112623401502000_2023.11.22.23298907v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.11.060"},{"key":"2023112623401502000_2023.11.22.23298907v1.21","doi-asserted-by":"crossref","unstructured":"Bell GJ , Gyaase S , Goel V , et al. Malaria Transmission Intensity and Parasitemia during the Three-Dose RTS,S\/AS01 Vaccination Series do not Reduce Magnitude of Antibody Response nor Efficacy Against the First Case of Malaria [Internet]. In Review; 2023 [cited 2023 Jun 8]. Available from: https:\/\/www.researchsquare.com\/article\/rs-2960373\/v1","DOI":"10.21203\/rs.3.rs-2960373\/v1"},{"key":"2023112623401502000_2023.11.22.23298907v1.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200841109"},{"key":"2023112623401502000_2023.11.22.23298907v1.23","doi-asserted-by":"crossref","first-page":"e68812","DOI":"10.7554\/eLife.68812","article-title":"Impact of asymptomatic Plasmodium falciparum infection on the risk of subsequent symptomatic malaria in a longitudinal cohort in Kenya","volume":"10","year":"2021","journal-title":"eLife"},{"key":"2023112623401502000_2023.11.22.23298907v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30104-4"},{"key":"2023112623401502000_2023.11.22.23298907v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206966"},{"key":"2023112623401502000_2023.11.22.23298907v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00332-7"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.11.22.23298907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:45:25Z","timestamp":1768506325000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.11.22.23298907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1101\/2023.11.22.23298907","relation":{"has-review":[{"id-type":"doi","id":"10.1162\/2e3983f5.7a424d40","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.796fae45","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.3b2322e0","asserted-by":"object"},{"id-type":"doi","id":"10.1162\/2e3983f5.c1c762df","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2023,11,23]]},"subtype":"preprint"}}